Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

Revenues for LUPIN are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 1.899000
forwardPE 22.266193
debtToEquity 29.388000
earningsGrowth 0.890000
revenueGrowth 0.319000
grossMargins 0.737950
operatingMargins 0.242440
trailingEps 116.420000
forwardEps 101.768630

LUPIN's current ratio, being 1.899, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, LUPIN is well-equipped to meet its immediate financial obligations without any difficulties.
Lupin Limited's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
LUPIN's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving LUPIN a stronger position in managing its financial obligations.
LUPIN's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as LUPIN's increasing profits and sales signal further growth in the near future.
LUPIN's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
LUPIN's forward EPS is lower than its trailing EPS, indicating the company may experience reduced profitability. This signals that the company's earnings growth could slow down in the near future.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

Over time, price projections for LUPIN have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for LUPIN's continued growth.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


With analysts showing a buy bias for Lupin Limited, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning Lupin Limited as a safe and profitable place for investors to allocate their funds and seek growth.